跳至主要内容
临床试验/IRCT20230801058996N3
IRCT20230801058996N3招募中1 期

Safety and efficacy of cell therapy with allogeneic natural killer cells activated with interleukin 2 and 15 in patients with refractory non-M3 acute myeloid leukemia (absence of hematological, morphological or molecular response after at least two treatment regimens)

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12 years 至 80 years(—)
性别
All

入选标准

  • Patients with acute myeloid leukemia(non-M3) diagnosed according to the World Health Organization classification
  • Inadequate response to induction therapy (incomplete or complete remission with minimal positive residual disease)
  • Relapse (Hematologic, morphologic or positive minimal residual disease)
  • Karnofsky index above 70%

排除标准

  • Patients with acute myeloid leukemia-M3
  • Patients with low-risk acute myeloid leukemia
  • Patients in complete molecular remission

研究者

相似试验